@article{Egeberg_Kristensen_Vender_Zaheri_El Baou_Gallo_Riedl_Schuster_2022, title={Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3}, volume={102}, url={https://medicaljournalssweden.se/actadv/article/view/2269}, DOI={10.2340/actadv.v102.2269}, abstractNote={<p class="p1"><span class="s1">Nail psoriasis is a chronic, difficult-to-treat condition affecting almost half of patients with psoriasis. It is associated with considerable social stigma and impairment of patients’ quality of life. The aim of this study was to assess improvements in objective measures of nail psoriasis among patients from the long-term extension of the UNCOVER-3 study who received the interleukin-17A inhibitor ixekizumab and had either any degree of nail psoriasis (Nail Psoriasis Severity Index (NAPSI) >=1) or significant nail psoriasis (fingernail NAPSI ≥ 16 and ≥ 4 fingernails involved) at baseline. Efficacy outcomes reported through week 264 included the mean percentage improvements from baseline in NAPSI score and the proportion of patients achieving nail psoriasis resolution (NAPSI=0). In UNCOVER-3, 56.9% (219/385) of patients had nail psoriasis at baseline; of those, 61.2% (134/219) had significant nail psoriasis. At week 60, a total of 66.9% and 59.1% of patients with baseline nail psoriasis and significant baseline nail psoriasis, respectively, reported complete clearance of nail psoriasis, an effect which was sustained through week 264. This analysis demonstrates that continuous treatment with ixekizumab in adult patients with moderate-to-severe-psoriasis through 264 weeks was associated with improvements and clearance of fingernail psoriasis, irrespective of the severity of nail psoriasis at baseline.</span></p>}, journal={Acta Dermato-Venereologica}, author={Egeberg, Alexander and Kristensen, Lars Erik and Vender, Ronald and Zaheri, Shirin and El Baou, Celine and Gallo, Gaia and Riedl, Elisabeth and Schuster, Christopher}, year={2022}, month={Oct.}, pages={adv00787} }